Log In Sign up
The largest database of trusted experimental protocols

Igg1 anti human cd133 1 clone ac133

Manufactured by Miltenyi Biotec
Visit Supplier
Sourced in Germany

The IgG1) anti-human CD133/1 (clone AC133) is a monoclonal antibody targeting the CD133 antigen, which is expressed on various stem and progenitor cells. This antibody can be used for the detection and isolation of CD133-positive cells.

Automatically generated - may contain errors

Lab products found in correlation

Attune nxt flow cytometer, by Thermo Fisher Scientific (4 mentions) Fcr blocking reagent, by Miltenyi Biotec (1 mentions) Facscalibur flow cytometer, by BD (1 mentions)

Spelling variants of this product

CD133 (122 citations) Anti-CD133 (35 citations) AC133 (16 citations) Anti-human CD133/1 (AC133) (2 citations) Human IgG1 (1 citations)

5 protocols using igg1 anti human cd133 1 clone ac133

1

CD133 Expression in HuH6 and PIM3 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
HuH6 WT or PIM3 KO cells (1 × 106) were labeled with allophycocyanin (APC)-conjugated mouse immunoglobulin G1 (IgG1) anti-human CD133/1 (clone AC133, Miltenyi Biotec, Waltham, MA) according to the manufacturer’s instructions. Unlabeled cells were used as negative controls. The percent of cells positive for APC was determined via flow cytometry using the Attune™ NxT Flow Cytometer (Invitrogen™, Thermo Fisher).
Marayati R., Stafman L.L., Williams A.P., Bownes L.V., Quinn C.H., Markert H.R., Easlick J.L., Stewart J.E., Crossman D.K., Mroczek-Musulman E, & Beierle E.A. (2021). CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells. Cancer gene therapy, 29(5), 558-572.
+ Open protocol
+ Expand
2

Evaluating CD133 Expression in PDX Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
CD133 cell surface expression was evaluated by flow cytometry. PDX cells (3 × 106) were first plated in a 6-well plate and treated with 10 or 25 μM of 6-Me for 24 hours. Cells were then incubated with an FcR Blocking Reagent (Miltenyi Biotec, Bergisch Gladbach, Germany) prior to being labeled with an Allophycocyanin (APC)-conjugated mouse immunoglobulin G1 (IgG1) anti-human CD133/1 (clone AC133, Miltenyi Biotec) according to the manufacturer’s instructions. Unlabeled cells were used as negative controls. The Attune™ NxT Flow Cytometer (Invitrogen™) was used to quantify the percentage of cells positive for CD133/APC and data were analyzed using the FlowJo software (FlowJo, LLC)
Marayati R., Bownes L.V., Quinn C.H., Wadhwani N., Williams A.P., Markert H.R., Atigadda V., Aye J.M., Stewart J.E., Yoon K.J, & Beierle E.A. (2021). Novel Second-Generation Rexinoid Induces Growth Arrest and Reduces Cancer Cell Stemness in Human Neuroblastoma Patient-Derived Xenografts. Journal of pediatric surgery.
+ Open protocol
+ Expand
3

CD133 Expression Quantification in Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
Flow cytometry was used to evaluate the cell surface expression levels of CD133. HuH6 or HLM_3 cells (1 × 106) were labeled with allophycocyanin (APC)-conjugated mouse immunoglobulin G1 (IgG1) anti-human CD133/1 (clone AC133, Miltenyi Biotec, Waltham, MA) according to the manufacturer’s instructions. The percent of cells positive for APC was determined via flow cytometry using the Attune™ NxT Flow Cytometer (Invitrogen™, Thermo Fisher).
Marayati R., Julson J.R., Bownes L.V., Quinn C.H., Hutchins S.C., Williams A.P., Markert H.R., Beierle A.M., Stewart J.E., Hjelmeland A.B., Mroczek-Musulman E, & Beierle E.A. (2022). Metastatic Human Hepatoblastoma Cells Exhibit Enhanced Tumorigenicity, Invasiveness and a Stem Cell-Like Phenotype. Journal of pediatric surgery, 57(6), 1018-1025.
+ Open protocol
+ Expand
4

CD133 Expression Quantification in RA/UAB30-Treated Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
Following treatment with increasing doses of RA or UAB30 (0, 25, 50 μM for COA3 and 0, 10, 25 μM for COA6) for 24 h, cells (3 × 106) were labeled with an Allophycocyanin (APC)-conjugated mouse immunoglobulin G1 (IgG1) anti-human CD133/1 (clone AC133, Miltenyi Biotec) according to the manufacturer's instructions. Unlabeled cells were used as negative controls. The percentage of cells positive for APC was determined via flow cytometry using the FACSCalibur™ Flow Cytometer (BD Biosciences) and analyzed using the FlowJo software (FlowJo, LLC), quantifying the percentage of cells positive for CD133.
Marayati R., Bownes L.V., Stafman L.L., Williams A.P., Quinn C.H., Atigadda V., Aye J.M., Stewart J.E., Yoon K.J, & Beierle E.A. (2020). 9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts. Translational Oncology, 14(1), 100893.
+ Open protocol
+ Expand
5

CD133 Expression in HuH6 and PIM3 Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
HuH6 WT or PIM3 KO cells (1 × 106) were labeled with allophycocyanin (APC)-conjugated mouse immunoglobulin G1 (IgG1) anti-human CD133/1 (clone AC133, Miltenyi Biotec, Waltham, MA) according to the manufacturer’s instructions. Unlabeled cells were used as negative controls. The percent of cells positive for APC was determined via flow cytometry using the Attune™ NxT Flow Cytometer (Invitrogen™, Thermo Fisher).
Marayati R., Stafman L.L., Williams A.P., Bownes L.V., Quinn C.H., Markert H.R., Easlick J.L., Stewart J.E., Crossman D.K., Mroczek-Musulman E, & Beierle E.A. (2021). CRISPR/Cas9-mediated knockout of PIM3 suppresses tumorigenesis and cancer cell stemness in human hepatoblastoma cells. Cancer gene therapy, 29(5), 558-572.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!